KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit
https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. So what: If you purchased Kyverna common stock you may […]